Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00542308 · ClinicalTrials.gov registry record · Phase 2
Zalutumumab in Non-curable Patients With SCCHN
A Phase 2 study, sponsored by Genmab.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00542308: Completed Phase 2 study, sponsored by Genmab.
NCT00542308 is a Phase 2 study that has completed, run by Genmab. The registered enrollment target is 90 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00542308, a Phase 2 study, has completed, sponsored by Genmab.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
Primary Outcome
OS was defined as time from start of treatment until date of death of any cause.
Interventions
- DRUG Zalutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00542308 record still lists
NCT00542308 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which Zalutumumab is the first listed.
NCT00542308 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00542308 about?
NCT00542308 is a clinical study titled "Zalutumumab in Non-curable Patients With SCCHN". Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
What is the current status of trial NCT00542308?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2008-01. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00542308?
The interventions under investigation include: Zalutumumab (DRUG).
Who is sponsoring clinical trial NCT00542308?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00542308's enrollment target sits among peer trials
90 772nd of 2000 higher than 1,199 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia